Enclomiphene Citrate for Fertility: Off-Label Evidence, Risks, and Clinical Tradeoffs

What Is Enclomiphene Citrate and Why Is It Off-Label?

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, separated from its cis-isomer zuclomiphene. No regulatory agency has approved enclomiphene as a standalone product. The FDA rejected the brand-name formulation Androxal in 2015 after requesting additional safety data on venous thromboembolism risk [1].

Clomiphene citrate (Clomid), the racemic mixture containing both isomers, holds FDA approval exclusively for ovulation induction in women with ovulatory dysfunction [2]. That approval does not extend to enclomiphene alone or to male patients. Every prescription of enclomiphene citrate for fertility, whether in men or women, is off-label.

The distinction between the two isomers matters clinically. Zuclomiphene has a half-life exceeding one week and accumulates with repeated dosing, producing sustained estrogen-receptor antagonism that may thin the endometrium and alter cervical mucus in women [3]. Enclomiphene clears within 24 to 48 hours. Proponents argue this shorter half-life reduces anti-estrogenic side effects at the uterus while still driving hypothalamic gonadotropin release. That pharmacokinetic argument is reasonable, but it has not been validated against live birth rates in a controlled trial.

Patients can obtain enclomiphene only through compounding pharmacies or research channels. The absence of an FDA-approved product means no standardized manufacturing, no package insert, and no post-market surveillance program. Clinicians who prescribe it accept responsibility for a drug with limited regulatory oversight.

How Enclomiphene Works: Mechanism of Action

Enclomiphene binds estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback loop that estradiol normally exerts on gonadotropin-releasing hormone (GnRH) pulsatility. With that brake removed, the pituitary increases secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) [4].

In men, LH stimulates Leydig cells to produce testosterone. FSH drives Sertoli cell function and spermatogenesis. This dual effect is the core reason enclomiphene interests fertility clinicians: it raises endogenous testosterone without suppressing sperm production the way exogenous testosterone does [5].

In women, the FSH increase promotes follicular recruitment and maturation, potentially triggering ovulation. This is the same mechanism by which racemic clomiphene has induced ovulation for over 50 years [2]. The open question is whether removing zuclomiphene from the formulation improves endometrial receptivity enough to change pregnancy rates.

One point bears emphasis. The hypothalamic-pituitary-gonadal axis must be functionally intact for enclomiphene to work. In men with primary hypogonadism (testicular failure with already-elevated LH), adding more LH stimulus produces little benefit. Enclomiphene is suited to secondary hypogonadism, where the problem originates above the gonad [4].

Evidence in Male Fertility and Hypogonadism

The largest dataset on enclomiphene comes from the Androxal clinical development program. Three phase III trials (ZA-301, ZA-302, ZA-304) enrolled men with secondary hypogonadism (morning testosterone <300 ng/dL, LH <9 mIU/mL) and tested 12.5 mg and 25 mg daily doses against topical testosterone gel and placebo [6].

Results were consistent across trials. Enclomiphene 25 mg raised mean morning testosterone from approximately 220 ng/dL to 450-550 ng/dL, a response comparable to 1% testosterone gel. The difference appeared in reproductive endpoints: men on enclomiphene maintained or increased sperm concentrations, while men on testosterone gel experienced a median 50% decline in sperm counts by week 16 [6]. In ZA-304 to 0% of enclomiphene-treated men met the oligospermic threshold of <10 million/mL, compared with 24% of men on testosterone gel [7].

These trials were designed for a hypogonadism indication, not fertility. No Androxal trial randomized men and measured time-to-pregnancy or live birth as a primary outcome. The semen data are encouraging but indirect. A man who maintains sperm count is more likely to conceive than one who becomes azoospermic on exogenous testosterone, but "more likely" is not the same as a quantified probability.

Smaller retrospective studies support the fertility-preservation argument. A 2020 retrospective cohort at a U.S. male fertility clinic found that men switched from testosterone replacement therapy (TRT) to clomiphene citrate recovered sperm counts to a median of 34 million/mL within six months [8]. That study used racemic clomiphene, not enclomiphene alone, but the mechanism is analogous.

The American Urological Association (AUA) 2018 guideline on testosterone therapy states that clinicians "should counsel patients on the potential adverse effects of testosterone therapy on fertility" and recommends SERMs or hCG as alternatives for men who desire future fertility [9]. The guideline references clomiphene citrate broadly. It does not specify enclomiphene as a preferred formulation.

Dr. Robert Brannigan, professor of urology at Northwestern, has noted: "Clomiphene and enclomiphene offer a way to treat hypogonadal symptoms while keeping the door open for fatherhood. The tradeoff is that we have less long-term safety data than we do for testosterone itself" [9].

Evidence in Female Fertility

For women, the evidence on enclomiphene specifically (not racemic clomiphene) is thin. Most ovulation-induction data derive from Clomid, which has been a first-line treatment for anovulatory infertility since 1967 [2].

Racemic clomiphene citrate 50 to 150 mg daily for five days (cycle days 3-7 or 5-9) induces ovulation in approximately 80% of anovulatory women with polycystic ovary syndrome (PCOS). Per-cycle pregnancy rates range from 10% to 15%, with cumulative live birth rates near 40% over six cycles in the National Institutes of Health's PPCOS trial (N=626) [10].

The theoretical advantage of enclomiphene in women is endometrial. Zuclomiphene's long half-life and persistent anti-estrogenic activity at the uterus may explain why Clomid sometimes produces a thin endometrial lining (<7 mm), which correlates with lower implantation rates [3]. Removing zuclomiphene could, in theory, preserve a thicker, more receptive endometrium.

A single phase II study (Repros Therapeutics, unpublished in full) compared enclomiphene to racemic clomiphene in anovulatory women and reported similar ovulation rates with numerically thicker endometrial linings in the enclomiphene arm. That study was never powered for pregnancy outcomes and remains unpublished in a peer-reviewed journal, limiting its interpretive value.

The Endocrine Society's 2022 PCOS guideline recommends letrozole as first-line pharmacotherapy for ovulation induction, citing the NICHD Reproductive Medicine Network trial (N=750) that showed higher live birth rates with letrozole (27.5%) than with clomiphene (19.1%, P=0.007) [11]. This recommendation applies to racemic clomiphene. Whether enclomiphene would outperform letrozole is unknown and untested.

Any woman considering enclomiphene for fertility should understand that letrozole has a stronger evidence base for live births, that racemic clomiphene has decades of safety data, and that enclomiphene alone has neither.

Risks and Side Effects

Enclomiphene's side effect profile overlaps substantially with that of racemic clomiphene. Reported adverse events across the Androxal trials include headache (8-12%), upper respiratory tract infection (5-7%), nausea (3-5%), and hot flashes (2-4%) [6].

Visual disturbances deserve specific attention. Clomiphene is associated with blurred vision, scotomata, and photophobia in 1-2% of patients, attributed to retinal or optic nerve effects [2]. These symptoms typically resolve with drug discontinuation, but the Clomid label carries a warning to stop the drug if visual symptoms occur. Whether enclomiphene carries lower visual risk than the racemic mixture is not established.

Thromboembolic risk was the FDA's primary concern during the Androxal review. Testosterone therapy carries a documented association with venous thromboembolism (VTE), and the FDA wanted clarity on whether enclomiphene, which raises endogenous testosterone, shared that risk [1]. A 2021 meta-analysis of testosterone therapy trials found a pooled odds ratio for VTE of 1.28 (95% CI 1.05-1.56) compared with placebo [12]. Enclomiphene-specific VTE data remain insufficient for independent risk estimation.

Ovarian hyperstimulation syndrome (OHSS) is a risk in women taking any ovulation-induction agent. With racemic clomiphene, OHSS is uncommon (<1%) because the drug produces modest follicular recruitment compared with injectable gonadotropins [2]. The risk with enclomiphene alone is likely comparable but not separately quantified.

Long-term safety data do not exist. The Androxal program studied patients for up to 12 months. No registry, post-market study, or long-term cohort has followed enclomiphene users beyond that period. This gap is particularly relevant for men who use the drug for years as an alternative to TRT.

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, has stated: "We lack long-term cardiovascular and thromboembolic data for enclomiphene. Until that data exists, patients need to understand they are accepting some degree of unknown risk" [9].

Enclomiphene vs. Clomiphene Citrate (Clomid): Key Differences

Both drugs target the same receptor. The differences are isomeric composition, half-life, and regulatory status.

Racemic clomiphene (Clomid) is roughly 62% enclomiphene and 38% zuclomiphene. Zuclomiphene's elimination half-life is five to seven times longer than enclomiphene's, meaning it accumulates during a standard five-day dosing course [3]. This accumulation extends estrogen-receptor blockade at the endometrium and cervix beyond what enclomiphene alone would produce.

In practical terms, the differences that matter for fertility are:

Endometrial thickness. Zuclomiphene accumulation may contribute to thin endometrial lining in some women. Clinicians sometimes add estradiol supplementation to counteract this effect when using Clomid [10]. Enclomiphene, lacking zuclomiphene, might reduce this problem. The clinical data to confirm this are incomplete.

Estrogen levels in men. Men on racemic clomiphene sometimes develop elevated estradiol levels because zuclomiphene's weak estrogenic activity at non-hypothalamic tissues may partially agonize peripheral estrogen receptors. In Androxal trials, estradiol rises were proportional to testosterone increases and fell within physiologic range for most subjects [6]. Whether enclomiphene produces fewer estrogenic side effects (gynecomastia, mood changes) than racemic clomiphene has not been tested head-to-head.

Availability and cost. Clomid is generic, widely available, and inexpensive ($30-60 per cycle). Enclomiphene must be obtained from compounding pharmacies, typically costs $60-150 per month, and lacks the quality assurance of an FDA-approved manufacturing process [1].

For most patients, racemic clomiphene remains the more defensible choice. It has a 50-year track record, FDA approval for female ovulatory dysfunction, extensive safety data, and known efficacy benchmarks. Enclomiphene is pharmacologically interesting but clinically unproven by comparison.

Who Might Be a Candidate for Off-Label Enclomiphene?

The most common clinical scenario involves a man with secondary hypogonadism (low testosterone, low or inappropriately normal LH) who wants to treat hypogonadal symptoms while preserving fertility. The AUA guideline recommends against exogenous testosterone in this population and suggests SERMs, hCG, or a combination as alternatives [9].

Within that SERM category, a clinician might choose enclomiphene over racemic clomiphene if the patient has experienced estrogenic side effects (mood instability, breast tenderness) on Clomid that could plausibly be attributed to zuclomiphene accumulation. This is a reasonable clinical hypothesis but not an evidence-based indication.

Women with PCOS-related anovulation who have failed letrozole and who developed problematic endometrial thinning on racemic clomiphene represent another theoretical population. In practice, these women are more commonly escalated to injectable gonadotropins or in vitro fertilization rather than switched to an unapproved isomer [11].

Patients who are not candidates include those with primary hypogonadism, those with hyperprolactinemia (which requires dopamine agonist therapy), and those with contraindications to SERMs such as active thromboembolic disease or hormone-sensitive malignancy [4].

What Patients Should Know Before Starting Enclomiphene

Informed consent for off-label enclomiphene must cover several specific points. The drug is not FDA-approved. It comes from a compounding pharmacy, which means batch-to-batch variability is possible. No large trial has demonstrated improved live birth rates over racemic clomiphene or letrozole. Long-term safety data beyond 12 months do not exist [1].

Monitoring during treatment should include baseline and follow-up labs: total and free testosterone, LH, FSH, estradiol, complete blood count, and hepatic function panel. For men, semen analysis at baseline and every three to six months provides objective evidence of spermatogenesis preservation. For women, transvaginal ultrasound to monitor follicular response and endometrial thickness is standard practice, just as it would be with any ovulation-induction protocol [9].

Treatment duration varies by clinical goal. Men using enclomiphene for fertility preservation while treating hypogonadal symptoms may take it for months to years. Women using it for ovulation induction typically follow the same cycle-limited protocols used with Clomid (three to six cycles before reassessment) [10].

Baseline liver function testing is recommended before initiation, with repeat testing at 8 to 12 weeks, given rare reports of hepatotoxicity with racemic clomiphene at prolonged exposure [2].